Description

Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) produced using yeast expression systems. This vital cytokine plays a crucial role in stimulating the production, differentiation, and function of white blood cells, particularly neutrophils and macrophages. It is an essential active pharmaceutical ingredient (API) for the formulation of critical therapeutics used in oncology, hematology, and immunology. Pharmaceutical manufacturers and research institutions globally rely on high-purity Sargramostim CAS NO 123774-72-1 for developing treatments that support patient recovery from myelosuppressive events.

Application

• Oncological Support Therapy: Primary API for drugs used to accelerate myeloid recovery in patients undergoing bone marrow transplantation or intensive chemotherapy.
• Treatment of Neutropenia: Key component in therapeutics for patients with prolonged neutropenia following chemotherapy, radiation, or bone marrow transplant.
• Mobilization of Peripheral Blood Progenitor Cells (PBPC): Used in regimens to mobilize hematopoietic progenitor cells into the peripheral blood for collection and subsequent autologous transplantation.
• Research & Development: Critical reagent in immunological and hematological research for studying white blood cell proliferation, differentiation, and signaling pathways.
• Therapeutic Vaccine Adjuvant: Investigated for use as an immunostimulant and adjuvant in cancer vaccine development to enhance immune response.
• Treatment of Infectious Diseases: Explored as an adjunct therapy for certain fungal infections and in patients with AIDS-related neutropenia.

Basic Information

Product Name	Sargramostim
CAS No.	123774-72-1
Molecular Formula	C_{639}H_{1006}N_{168}O_{198}S_{8} (Approximate, for glycosylated protein)
Molecular Weight	~14.5 - 35 kDa (Glycosylated, microheterogeneous)
Synonyms	Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor; rhGM-CSF; GM-CSF; Molgramostim; Leukine® (Brand Name); Granulocyte-Macrophage Colony-Stimulating Factor; Colony-Stimulating Factor 2 (CSF2); Sargramostim; CSF-2; GMCSF; Pluripoietin-alpha; Macrophage Granulocyte Inducer; MGI.
EINECS	Contact for details

Quality Control

Our Sargramostim is manufactured under strict cGMP (current Good Manufacturing Practice) conditions to ensure the highest standards of purity, potency, and consistency required for pharmaceutical applications. Each batch undergoes comprehensive analytical testing including HPLC for purity and identity, biological activity assays (cell-based proliferation), tests for endotoxins and bioburden, and characterization of glycosylation patterns. Full traceability and compliance with ICH Q7 guidelines are maintained. A detailed Certificate of Analysis (COA) is provided with every shipment.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized (freeze-dried) powder at -20°C or below. Reconstituted solutions should be used immediately or stored at 2-8°C for a limited time as per stability data. This product is hygroscopic (moisture-sensitive); protect from humidity and allow vials to equilibrate to room temperature before opening to prevent condensation.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or solid
Identification (HPLC)	Conforms to reference standard
Identification (Bioassay)	Conforms to reference standard
Purity (RP-HPLC)	≥ 98.0%
Potency (Cell Proliferation Assay)	≥ 1.0 x 10^7 IU/mg
Endotoxin	< 5.0 EU/mg
Protein Content (UV)	Conforms
Moisture (Karl Fischer)	≤ 3.0%
pH (in solution)	6.5 - 7.5

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.